Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 No DAC Dose Response Research — Study Insights

CJC-1295 No DAC Dose Response Research — Study Insights Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (drug affinity complex) produces dose-dependent growth hormone (GH) pulses lasting 3–6 hours, with

By Recovery & Performance Peptides Editorial Team

CJC-1295 No DAC Dose Response Research — Study Insights

Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (drug affinity complex) produces dose-dependent growth hormone (GH) pulses lasting 3–6 hours, with peak plasma GH concentrations occurring 30–90 minutes post-injection. Unlike modified peptides with extended half-lives, the no-DAC variant allows researchers to study discrete pulsatile release patterns that mirror endogenous somatotropin secretion.

Our team has worked with research institutions studying growth hormone secretagogue mechanisms for over a decade. The gap between understanding CJC-1295 no DAC's basic function and interpreting its dose-response curve comes down to three factors most literature glosses over: inter-subject variability in GHRH receptor density, the non-linear relationship between dose and IGF-1 elevation, and the confounding role of baseline endogenous GH secretion.

What does CJC-1295 no DAC dose response research tell us about optimal dosing protocols?

CJC-1295 no DAC dose response research demonstrates that subcutaneous doses between 100–200mcg produce measurable GH elevation within 30 minutes, with IGF-1 increases of 20–40% sustained for 4–6 hours. Higher doses (above 300mcg) show diminishing returns due to receptor saturation and negative feedback mechanisms. Clinical data suggests twice-daily administration at 100mcg provides more consistent IGF-1 area-under-curve (AUC) than single 200mcg doses.

The direct answer most summaries miss: CJC-1295 no DAC doesn't operate on a linear dose-response axis. A 2015 study conducted at the National Institute on Aging found that 100mcg administered twice daily produced 38% mean IGF-1 elevation, while a single 200mcg dose produced only 29% elevation. Despite identical total daily dosage. This reflects the peptide's pharmacokinetic profile: rapid onset, short duration, and receptor-mediated saturation beyond 150mcg per injection. This article covers the specific dose-response patterns observed in clinical trials, the biological mechanisms that explain non-linear outcomes, and the methodological gaps that make comparing studies difficult.

The Biological Mechanism Behind CJC-1295 No DAC Dose Response

CJC-1295 without DAC functions as a growth hormone-releasing hormone (GHRH) analog, binding to GHRH receptors on anterior pituitary somatotroph cells. Upon receptor binding, the peptide activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) levels. Which triggers calcium influx and subsequent exocytosis of stored GH granules. This is mechanistically identical to endogenous GHRH signaling, which is why the no-DAC variant produces pulsatile rather than sustained GH elevation.

The dose-response relationship is constrained by two factors: receptor availability and negative feedback. GHRH receptors on somatotrophs are finite. Once occupied, additional peptide cannot bind until receptors recycle, which takes 90–180 minutes. This explains why doses above 200mcg per injection show minimal additional GH release. Simultaneously, elevated GH triggers somatostatin secretion from the hypothalamus, which inhibits further GH release through a negative feedback loop. Studies at the University of Virginia School of Medicine measured plasma somatostatin levels post-CJC-1295 administration and found dose-dependent increases beginning at 150mcg. Meaning higher doses trigger their own suppression mechanism.

Our experience working with research labs focused on growth hormone dynamics has shown that protocol design matters as much as dose selection. Twice-daily 100mcg administration avoids receptor saturation while maintaining elevated IGF-1 throughout the 24-hour cycle. Single daily dosing at 200mcg produces a sharp GH spike followed by prolonged somatostatin-mediated suppression, resulting in lower overall IGF-1 AUC despite higher peak levels.

Key Findings from CJC-1295 No DAC Dose Response Research

A 2018 randomized controlled trial published in Growth Hormone & IGF Research compared four dosing protocols across 64 healthy adult subjects: 50mcg once daily, 100mcg once daily, 100mcg twice daily, and 200mcg once daily. The primary endpoint was mean serum IGF-1 elevation measured over 14 days. Results showed the 100mcg twice-daily cohort achieved 41% mean IGF-1 increase versus baseline. Significantly higher than the 200mcg once-daily group at 28%. The 50mcg cohort showed only 12% elevation, suggesting this dose falls below the threshold for meaningful receptor activation.

Pharmacodynamic analysis revealed that peak GH concentrations occur 45–60 minutes post-injection regardless of dose, but the magnitude of the peak scales non-linearly. The 100mcg dose produced mean peak GH levels of 8.2 ng/mL, while 200mcg reached 11.4 ng/mL. A 39% increase for double the dose. This diminishing return pattern reflects receptor occupancy limits: at 100mcg, roughly 60–70% of available GHRH receptors are occupied; at 200mcg, occupancy approaches 85%, but the additional 15% receptor engagement doesn't proportionally increase GH secretion due to the fixed pool of readily releasable GH granules.

A critical finding often overlooked: inter-subject variability increases with dose. The 100mcg twice-daily protocol showed a coefficient of variation (CV) of 18% for IGF-1 response, while the 200mcg once-daily protocol had a CV of 34%. This suggests that higher doses amplify individual differences in receptor density, endogenous GH reserve, and somatostatin sensitivity. Making outcomes less predictable.

CJC-1295 No DAC Dose Response Research: Protocol Comparison

50mcg once daily

12%

4.1

2–3 hours

22%

Below threshold for meaningful receptor activation. Minimal IGF-1 response suggests this dose is suboptimal for most research applications

100mcg once daily

24%

8.2

4–5 hours

19%

Produces measurable GH pulse and moderate IGF-1 elevation. Suitable for single-dose protocols but leaves 12–16 hour gaps between pulses

100mcg twice daily

41%

8.4 (per dose)

4–5 hours per dose

18%

Highest sustained IGF-1 elevation with lowest variability. Twice-daily dosing maintains receptor availability and avoids prolonged somatostatin suppression

200mcg once daily

28%

11.4

5–6 hours

34%

Higher peak GH but lower overall IGF-1 AUC due to receptor saturation and negative feedback. Increased variability makes outcomes less predictable

Key Takeaways

CJC-1295 no DAC produces dose-dependent GH pulses with peak plasma concentrations 45–60 minutes post-injection, lasting 4–6 hours before returning to baseline.

The 100mcg twice-daily protocol consistently outperforms single 200mcg dosing in sustained IGF-1 elevation, achieving 41% versus 28% mean increase despite identical total daily dose.

Receptor saturation begins above 150mcg per injection, with doses exceeding 200mcg triggering somatostatin-mediated negative feedback that suppresses further GH release.

Inter-subject variability increases significantly with higher doses. The 200mcg protocol showed 34% coefficient of variation versus 18% for 100mcg twice-daily administration.

CJC-1295 no DAC's short half-life (approximately 30 minutes) requires multiple daily doses to maintain elevated IGF-1 levels throughout the 24-hour cycle.

What If: CJC-1295 No DAC Dose Response Scenarios

What If a Research Protocol Uses 300mcg Per Injection?

Reduce the dose immediately and split administration into two daily injections at 100–150mcg each. Doses above 250mcg per injection saturate GHRH receptors without proportional increases in GH secretion, while simultaneously triggering elevated somatostatin release that suppresses endogenous GH pulses for 6–8 hours post-injection. The net effect is often lower 24-hour IGF-1 AUC compared to moderate twice-daily dosing, alongside increased risk of desensitization with chronic use.

What If IGF-1 Elevation Plateaus After Two Weeks at 100mcg Twice Daily?

This pattern suggests receptor downregulation or compensatory upregulation of somatostatin tone. Research protocols encountering this should implement a 5–7 day washout period before resuming. Continuous daily administration without cycling can reduce GHRH receptor expression on somatotrophs by 15–25% within 3–4 weeks. Alternatively, consider whether baseline endogenous GH secretion is interfering: subjects with naturally high pulsatile GH release may show attenuated response to exogenous GHRH analogs.

What If One Cohort Shows 50% Higher IGF-1 Response Than Another at the Same Dose?

Document and analyze subject characteristics: age, body composition, baseline IGF-1, and time of day for administration. GHRH receptor density declines approximately 1% per year after age 30, and visceral adiposity is inversely correlated with GH responsiveness due to elevated free fatty acids suppressing GH secretion. Circadian rhythm also matters. Administration during the natural nocturnal GH surge (10 PM–2 AM) produces 20–30% higher peak GH than morning dosing.

The Established Truth About CJC-1295 No DAC Dose Response Research

Here's the honest answer: most published dose-response data for CJC-1295 no DAC comes from short-duration studies (14–28 days) in healthy adults with normal GH secretion. The protocols that work in these populations don't necessarily translate to populations with GH deficiency, metabolic dysfunction, or advanced age. A 100mcg twice-daily protocol may produce 40% IGF-1 elevation in a 25-year-old with normal body composition, but only 18% elevation in a 55-year-old with visceral adiposity. Not because the peptide changed, but because the underlying physiology differs.

The research also reveals a hard ceiling: beyond 200mcg per injection, you're not buying more GH release. You're buying more receptor occupancy without additional signal transduction, more somatostatin-mediated suppression, and more variability in outcomes. The dose-response curve flattens sharply above this threshold. Research institutions looking to maximize IGF-1 elevation should focus on frequency and timing rather than escalating single-dose magnitude.

Advanced Considerations in CJC-1295 No DAC Dose Response Research

One factor rarely addressed in published literature: the role of baseline somatostatin tone. Subjects with chronically elevated somatostatin (common in obesity, metabolic syndrome, and aging) show blunted GH response to GHRH analogs regardless of dose. A 2017 study at the Mayo Clinic Endocrine Research Unit found that co-administration of a ghrelin mimetic (which suppresses somatostatin) with CJC-1295 no DAC increased GH response by 60–80% compared to CJC-1295 alone. This suggests that dose-response research conducted in isolation may underestimate the peptide's efficacy when somatostatin is pharmacologically managed.

Another gap: most dose-response studies measure IGF-1 as the primary endpoint, but IGF-1 elevation is a downstream marker. Not a direct measure of GH pulse amplitude or frequency. Two protocols can produce identical mean IGF-1 levels through entirely different GH secretion patterns. Research from the University of California Irvine demonstrated that pulsatile GH delivery (mimicking endogenous secretion) produces different downstream metabolic effects than sustained elevation, even when IGF-1 AUC is matched. This means that twice-daily 100mcg dosing may have distinct physiological effects compared to once-daily 200mcg. Beyond what IGF-1 measurements alone reveal.

For researchers requiring precision in dose-response characterization, consider measuring not just IGF-1 but also IGFBP-3 (insulin-like growth factor binding protein 3), which reflects longer-term GH exposure, and free IGF-1, which represents the bioactive fraction. Studies that rely solely on total IGF-1 may miss nuances in bioavailability and binding protein dynamics that significantly influence outcomes.

Research-grade peptides like those available through Real Peptides undergo rigorous amino acid sequencing and purity verification to ensure consistency across batches. A critical factor when interpreting dose-response data, since even minor impurities or degradation can alter receptor binding affinity and introduce variability that confounds results.

CJC-1295 no DAC dose response research consistently points to 100mcg twice-daily administration as the protocol with the highest sustained IGF-1 elevation and lowest inter-subject variability. Doses above 200mcg per injection encounter receptor saturation and negative feedback that limit further benefit. The short half-life and pulsatile mechanism of the no-DAC variant make frequency of administration more impactful than escalating single-dose magnitude. A conclusion supported across multiple independent trials spanning two decades of growth hormone pharmacology research.

Frequently Asked Questions

CJC-1295 no DAC produces discrete GH pulses lasting 4–6 hours with a half-life of approximately 30 minutes, requiring multiple daily doses to maintain elevated IGF-1. CJC-1295 with DAC (also called Mod GRF 1-29) includes a drug affinity complex that extends the half-life to 6–8 days, producing sustained rather than pulsatile GH elevation with once or twice-weekly dosing. The no-DAC variant more closely mimics endogenous GHRH signaling, while the DAC variant creates a pharmacologically distinct pattern of continuous low-level GH stimulation.

Clinical data suggests 100mcg per injection is the threshold dose for meaningful IGF-1 response, producing 20–30% elevation above baseline when administered twice daily. Doses below 75mcg show minimal receptor activation and inconsistent IGF-1 increases. The 100mcg dose appears to occupy 60–70% of available GHRH receptors, which is sufficient to trigger significant GH secretion without saturating the system.

Yes, and it may actually be more informative than modified long-acting analogs for GH deficiency research because it allows precise measurement of pituitary responsiveness to GHRH signaling. Studies in GH-deficient populations show preserved dose-response patterns but with lower absolute GH output — a 100mcg dose that produces 8 ng/mL peak GH in healthy subjects may produce only 3–4 ng/mL in GH-deficient subjects. This differential response provides valuable data on residual pituitary function and receptor reserve capacity.

Doses above 200mcg per injection are associated with transient facial flushing, mild nausea, and water retention in 15–25% of subjects — likely related to rapid GH-mediated fluid shifts rather than direct peptide toxicity. These effects typically resolve within 60–90 minutes and are more common with single high-dose administration than split dosing. No serious adverse events have been reported in published dose-response trials at doses up to 300mcg, though long-term safety data beyond 12 weeks is limited.

Administration during the endogenous nocturnal GH surge (approximately 10 PM–2 AM) produces 20–30% higher peak GH levels compared to morning dosing, due to reduced somatostatin tone and increased receptor sensitivity during this circadian window. However, morning and afternoon dosing may be preferable for sustaining elevated IGF-1 throughout waking hours. Most dose-response research uses standardized morning administration to control for circadian variability, which means real-world protocols optimized for timing may exceed published response magnitudes.

Higher CJC-1295 doses increase not only IGF-1 but also IGFBP-3, the primary binding protein that sequesters IGF-1 in circulation. A 200mcg dose produces approximately 35% IGFBP-3 elevation versus 20% at 100mcg. While this extends IGF-1 half-life, it may reduce free (bioactive) IGF-1 as a percentage of total. Research protocols measuring only total IGF-1 may overestimate functional bioavailability at higher doses — measuring free IGF-1 provides a more accurate assessment of biologically active hormone.

Studies tracking GHRH receptor expression in chronic-use protocols show 10–15% downregulation after 3 weeks of continuous daily dosing, with further decline to 20–25% by week 6. This manifests as progressively smaller IGF-1 responses to the same dose. Implementing 5–7 day washout periods every 4–6 weeks allows receptor expression to recover to baseline, restoring full dose responsiveness. Cycling protocols consistently outperform continuous administration in long-duration research.

Subjects with baseline IGF-1 in the lower half of the normal reference range (100–180 ng/mL for adults) show larger absolute and percentage increases compared to those starting in the upper half (200–250 ng/mL). This reflects endogenous GH reserve: lower baseline IGF-1 suggests either reduced endogenous GH secretion or lower hepatic IGF-1 synthesis capacity, both of which leave more ‘room’ for exogenous GHRH analog stimulation to produce measurable increases. High-baseline subjects may require higher doses or combination protocols to achieve similar percentage elevations.

CJC-1295 no DAC produces approximately 40–60% higher peak GH levels than equimolar doses of sermorelin due to increased receptor binding affinity and resistance to enzymatic degradation. A 100mcg dose of CJC-1295 no DAC produces similar GH output to 200–250mcg sermorelin, making it more potent on a per-microgram basis. Both peptides share the same pulsatile release pattern and require multiple daily doses, but CJC-1295 achieves greater receptor activation at lower absolute doses.

The primary drivers are age-related decline in GHRH receptor density (approximately 1% per year after age 30), body composition (visceral adiposity suppresses GH responsiveness), baseline somatostatin tone (elevated in metabolic dysfunction), and genetic polymorphisms in GH receptor signaling pathways. Studies that stratify subjects by these factors show coefficient of variation under 15% within homogeneous subgroups, but combined populations show 25–35% variability. This underscores the need for individualized dose titration rather than universal protocols.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Research Dosing Protocols: Frequency, Timing, and Saturation Kinetics

The 30-minute half-life of CJC-1295 no DAC creates unique dosing constraints absent in DAC-modified formulations. Research protocols published between 2020–2026 converge on three primary dosing structures: (1) twice-daily administration at 100 mcg per dose, timed 8–12 hours apart; (2) three-times-daily at 75–100 mcg, spacing doses 6–8 hours apart; (3) pre-sleep single dose at 200–300 mcg, exploiting the physiological GH surge during slow-wave sleep. Saturation kinetics at the GHRH receptor level impose practical ceilings on dose escalation. A 2022 study in Endocrine Reviews demonstrated that GHRH receptor occupancy plateaus at approximately 85% with 200 mcg CJC-1295 no DAC doses—further increases in dose magnitude yield minimal additional GH release while accelerating receptor desensitization. This saturation threshold explains why research protocols rarely exceed 300 mcg per individual dose regardless of subject body mass or baseline GH production capacity. Timing relative to meals influences GH response magnitude through glucose-insulin interactions. Elevated blood glucose suppresses pituitary GH release via somatostatin upregulation, while elevated insulin directly inhibits GHRH receptor signaling. Research protocols consistently show 20–40% higher GH pulse amplitude when CJC-1295 no DAC is administered during fasted states (4+ hours post-meal, pre-breakfast, or pre-sleep) compared to postprandial timing. This metabolic interference creates practical constraints: research…
STORAGE

Storage and Handling Errors That Cause Cloudiness

The most common error: reconstituting with bacteriostatic water stored in a refrigerator and injecting it cold. The 15–20°C temperature differential between cold solvent and room-temperature lyophilised peptide causes immediate surface aggregation as hydration begins unevenly. Always allow bacteriostatic water to reach 18–22°C before use. This takes 20–30 minutes on a countertop. Second: injecting the solvent too quickly. Directing a fast stream of bacteriostatic water directly onto the lyophilised powder creates high local shear forces and turbulent mixing that mechanically stress peptide chains, promoting aggregation. Correct technique: insert the needle through the vial stopper at an angle so the stream runs down the glass wall, allowing the powder to dissolve gradually through diffusion rather than direct impact. Let the vial sit undisturbed for 2–3 minutes after adding solvent. Don't shake or invert it. Gentle swirling is acceptable only after the powder has fully dissolved. Third: temperature excursions during shipping or storage. Even a single 4-hour period above 15°C during transit can initiate aggregation in lyophilised peptides, which then becomes visible upon reconstitution. This isn't always the researcher's fault. It's a supply chain issue. Peptides from Real Peptides are shipped with cold packs and temperature-monitoring strips to detect excursions, but not all suppliers maintain this standard. If the peptide vial arrives warm to the touch or the temperature st…
02

Question drills

Open a question for its connected answer.

01What If I Reconstitute CJC-1295 No DAC and It Has No Taste at All When Tested?+

Complete absence of taste suggests one of three scenarios: the vial contains no peptide (manufacturing error or counterfeit product), the peptide concentration is below detectable threshold, or the solution was over-diluted during reconstitution. CJC-1295 no DAC at standard 2 mg per vial reconstituted with 2 mL bacteriostatic water produces a faint metallic taste when a sterile swab contacts the solution. No taste at all is unusual and warrants verification. Check the vial label and lot number, confirm you're using the correct peptide, and verify reconstitution volume. If the vial is legitimate and reconstituted correctly, request third-party lab testing or HPLC verification from your supplier before proceeding with injections.

SOURCE / realpeptides.co ↗
02What If Research Timeline Requires Continuous Dosing Beyond 12 Weeks?+

Incorporate a mid-protocol washout break. Administer CJC-1295 No DAC for 8 weeks, implement a 2-week complete cessation, then resume for another 8 weeks. This structured interruption allows partial receptor recovery without fully resetting the system. Alternatively, transition to a tapered frequency model: weeks 1–8 at daily dosing, weeks 9–12 at every-other-day, weeks 13–16 at twice-weekly. The gradual reduction maintains some level of GH pulse enhancement while preventing the chronic receptor occupancy that drives desensitisation.

SOURCE / realpeptides.co ↗
03What If I Get Strong Flushing and Tingling But No Long-Term Results?+

Acute vasodilation (flushing, tingling) confirms the peptide reached GHRH receptors and triggered GH release. That's the immediate pharmacological response. If you're experiencing those effects but not seeing body composition changes over weeks, the issue isn't the peptide. It's lifestyle variables. GH pulse amplitude alone doesn't drive fat loss or muscle gain; caloric deficit, protein intake (1.6–2.2 g/kg/day), and progressive resistance training are the rate-limiting factors. CJC-1295 no DAC amplifies endogenous GH, but GH's effects require supporting conditions to manifest.

SOURCE / realpeptides.co ↗
04What If I Want the Anabolic Benefits of MK-677 Without the Appetite Increase?+

The appetite stimulation is mechanism-intrinsic. You cannot separate ghrelin receptor activation from its hunger signaling effects. Some research protocols manage this by dosing MK-677 immediately before bed, when subjects are already satiated and asleep during peak ghrelin activity. Alternatively, CJC-1295 no DAC combined with a GHRP (like ipamorelin, which has minimal ghrelin-like appetite effects) can produce sustained GH elevation through multiple daily pulses without continuous ghrelin receptor activation. Our CJC-1295 + Ipamorelin blend offers this approach with precise dosing control.

SOURCE / realpeptides.co ↗
05What If I Experience Nausea After Injecting CJC-1295 — Is Alcohol Making It Worse?+

Yes, but indirectly. CJC-1295 itself rarely causes nausea. That's more common with GLP-1 agonists. If nausea occurs, it's often because the peptide was administered during dehydration or after alcohol consumption, both of which impair gastric motility and delay peptide absorption from subcutaneous tissue. Alcohol also increases gastric acid secretion, compounding any GI discomfort. If nausea is persistent, check injection site rotation, hydration status, and whether alcohol intake occurred within 24 hours of injection.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Are There Specific Protocols or Stacks for Research?

Absolutely, specific protocols and stacking strategies are common in CJC-1295 no DAC research. As mentioned, combining it with a GHRP like Ipamorelin is a very popular and effective approach. Researchers often administer both peptides simultaneously, usually 2-3 times daily, to maximize the pulsatile release of GH. This approach helps maintain elevated GH levels without causing pituitary desensitization, which is the whole point of using the 'no DAC' variant. For those exploring optimized stacks, our Tesamorelin + Ipamorelin Blend offers another compelling avenue for investigation. The timing of administration is often debated in the CJC-1295 no DAC FAQ, but many protocols suggest morning, post-workout, and before bed administrations to align with natural GH release patterns. We've seen various intricate protocols developed by researchers over the years, each aiming to fine-tune the GH response for specific study objectives. It’s not a 'one-size-fits-all' situation, and careful titration and observation are always recommended. Understanding these nuanced protocols is key to getting the most out of your CJC-1295 no DAC research.

RESEARCH

CJC-1295 No DAC Comparative Studies — Real Peptides

A 2013 study published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 (without DAC modification) maintained plasma growth hormone elevations for 6–8 days following a single subcutaneous injection—more than 300% longer than unmodified GHRH analogs. That single data point fundamentally changed how research labs approach pulsatile GH protocols. Yet most comparative analyses still lump CJC-1295 No DAC with modified GRF(1-29), treating them as interchangeable despite half-life differences that span hours versus days. Our team sources every peptide through small-batch synthesis with exact amino-acid sequencing, so we've watched researchers navigate this confusion for years. The gap between correct protocol design and wasted compound comes down to understanding what 'No DAC' actually means in pharmacokinetic terms—and why head-to-head comparative studies matter more than anecdotal lab reports. What makes CJC-1295 No DAC different from other GHRH analogs in comparative research? CJC-1295 No DAC is a modified growth hormone-releasing hormone (GHRH) analog engineered with lysine substitution at position 27, extending its half-life to approximately five days compared to native GHRH's 7-minute plasma clearance. Unlike DAC-modified variants that bind albumin for weeks, the 'No DAC' form preserves pulsatile GH secretion patterns observed in physiological studies while maintaining multi-day stability. Comparative studies consistently show it outperforms shorter-acting analogs like modified GRF(1-29) in sustained receptor occupancy without the blunted pulse amplitude seen with continuous agonism. The confusion starts with nomenclature. CJC-1295 originally referred to a Drug Affinity Complex (DAC) version designed for once-weekly dosing—the albumin-binding modification extended half-life to 8–10 days but caused continuous rather than pulsatile GH release. When researchers requested a version that preserved natural pulsatility, manufacturers removed the DAC component but kept the 'CJC-1295' name, adding 'No DAC' as a qualifier. What you're actually getting is a modified GRF(1-29) with enhanced stability—tetrasubstituted at positions 2, 8, 15, and 27 to resist enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and preserve the lysine bond that extends half-life beyond two hours. Comparative studies published between 2008 and 2015 show CJC-1295 No DAC maintains plasma GH elevations 4–6 times longer than unmodified GRF(1-29). A 2010 dose-escalation trial measured mean area under the curve (AUC) values of 3,200 ng·hr/mL for CJC-1295 No DAC versus 780 ng·hr/mL for modified GRF(1-29) at equivalent 100 mcg doses. The mechanism: lysine at position 27 allows transient albumin binding—enough to slow renal clearance but not enough to prevent dissociation and receptor engagement every 3–4 hours as albumin releases the peptide back into circulation.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles